Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 22 studies | 54% ± 15% | |
lung | 19 studies | 53% ± 14% | |
brain | 15 studies | 31% ± 14% | |
intestine | 14 studies | 41% ± 18% | |
eye | 11 studies | 47% ± 20% | |
kidney | 9 studies | 58% ± 13% | |
liver | 8 studies | 47% ± 16% | |
lymph node | 7 studies | 57% ± 15% | |
bone marrow | 6 studies | 53% ± 20% | |
uterus | 6 studies | 53% ± 22% | |
pancreas | 5 studies | 61% ± 25% | |
prostate | 5 studies | 44% ± 17% | |
placenta | 4 studies | 80% ± 21% | |
breast | 4 studies | 53% ± 11% | |
ovary | 3 studies | 38% ± 11% | |
heart | 3 studies | 28% ± 10% | |
adipose | 3 studies | 42% ± 20% | |
adrenal gland | 3 studies | 50% ± 14% | |
esophagus | 3 studies | 63% ± 25% | |
skin | 3 studies | 42% ± 13% | |
thymus | 3 studies | 65% ± 31% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 100% | 74505.68 | 1809 / 1809 | 100% | 1295.88 | 470 / 472 |
ovary | 100% | 24003.34 | 180 / 180 | 100% | 780.01 | 428 / 430 |
brain | 100% | 40121.57 | 2633 / 2642 | 100% | 759.87 | 703 / 705 |
uterus | 99% | 23879.15 | 168 / 170 | 100% | 1371.28 | 458 / 459 |
kidney | 100% | 58011.54 | 89 / 89 | 98% | 1476.77 | 882 / 901 |
bladder | 100% | 39383.14 | 21 / 21 | 98% | 1043.79 | 493 / 504 |
breast | 100% | 34636.91 | 459 / 459 | 98% | 624.88 | 1093 / 1118 |
esophagus | 100% | 55033.13 | 1444 / 1445 | 98% | 664.77 | 179 / 183 |
intestine | 100% | 30723.03 | 966 / 966 | 98% | 834.12 | 515 / 527 |
thymus | 100% | 24836.28 | 650 / 653 | 98% | 483.15 | 594 / 605 |
lung | 99% | 40564.40 | 575 / 578 | 98% | 1222.49 | 1134 / 1155 |
prostate | 100% | 25310.91 | 244 / 245 | 97% | 428.87 | 489 / 502 |
stomach | 96% | 21572.77 | 346 / 359 | 95% | 633.64 | 272 / 286 |
liver | 97% | 28499.34 | 219 / 226 | 89% | 498.35 | 360 / 406 |
adrenal gland | 100% | 33276.75 | 257 / 258 | 63% | 366.46 | 144 / 230 |
pancreas | 67% | 8842.02 | 219 / 328 | 95% | 645.69 | 169 / 178 |
adipose | 100% | 37801.85 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 1299.46 | 29 / 29 |
spleen | 100% | 32529.85 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 1642.49 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 315.49 | 1 / 1 |
blood vessel | 100% | 47899.47 | 1330 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 84947.14 | 921 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 739.61 | 79 / 80 |
heart | 82% | 15614.64 | 710 / 861 | 0% | 0 | 0 / 0 |
muscle | 68% | 9993.13 | 549 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0010756 | Biological process | positive regulation of plasminogen activation |
GO_0006096 | Biological process | glycolytic process |
GO_0045933 | Biological process | positive regulation of muscle contraction |
GO_0009615 | Biological process | response to virus |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0061621 | Biological process | canonical glycolysis |
GO_0006094 | Biological process | gluconeogenesis |
GO_1903298 | Biological process | negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_2001171 | Biological process | positive regulation of ATP biosynthetic process |
GO_0030308 | Biological process | negative regulation of cell growth |
GO_0005615 | Cellular component | extracellular space |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0000015 | Cellular component | phosphopyruvate hydratase complex |
GO_0005640 | Cellular component | nuclear outer membrane |
GO_0009986 | Cellular component | cell surface |
GO_0005829 | Cellular component | cytosol |
GO_0005938 | Cellular component | cell cortex |
GO_0005737 | Cellular component | cytoplasm |
GO_0031430 | Cellular component | M band |
GO_0005634 | Cellular component | nucleus |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
GO_0045296 | Molecular function | cadherin binding |
GO_0051020 | Molecular function | GTPase binding |
GO_0004634 | Molecular function | phosphopyruvate hydratase activity |
GO_0001222 | Molecular function | transcription corepressor binding |
GO_0003714 | Molecular function | transcription corepressor activity |
GO_0000287 | Molecular function | magnesium ion binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | ENO1 |
Protein name | phosphopyruvate hydratase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) Alpha-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (C-myc promoter-binding protein) (Enolase 1) (MBP-1) (MPB-1) (Non-neural enolase) (NNE) (Phosphopyruvate hydratase) (Plasminogen-binding protein) Enolase 1 |
Synonyms | MBPB1 ENO1L1 MPB1 |
Description | FUNCTION: Glycolytic enzyme the catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate . In addition to glycolysis, involved in various processes such as growth control, hypoxia tolerance and allergic responses . May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons . Stimulates immunoglobulin production . .; FUNCTION: [Isoform MBP-1]: Binds to the myc promoter and acts as a transcriptional repressor. May be a tumor suppressor. . |
Accessions | P06733 K7EM90 A0A2R8Y798 ENST00000643438.1 A0A2R8YEG5 ENST00000646370.2 A0A2R8YEM5 ENST00000497492.1 A0A2R8Y879 ENST00000646660.1 ENST00000646156.1 K7ERS8 ENST00000647408.1 A0A2R8Y6I8 ENST00000489867.2 A4QMW8 ENST00000234590.10 [P06733-1] ENST00000646680.1 ENST00000646906.1 A0A2R8Y6G6 |